APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Stromal Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Gastrointestinal Stromal Tumor Drug Industry Growth and Trends Forecast to 2032

28 December 2025120 pages

Choose your research edition.

Industry ResearchGastrointestinal Stromal Tumor Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Stromal Tumor Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Stromal Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Stromal Tumor Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Stromal Tumor Drug Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Gastrointestinal Stromal Tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Gastrointestinal Stromal Tumor Drug include China Biopharmaceuticals, Zai Lab, CSPC Pharmaceuticals, Novartis, Mylan Pharms Inc., Kelun Pharmaceuticals, CStone Pharmaceuticals, Hansoh Pharmaceuticals and Vannsh Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Gastrointestinal Stromal Tumor Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Gastrointestinal Stromal Tumor Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Gastrointestinal Stromal Tumor Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Gastrointestinal Stromal Tumor Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Gastrointestinal Stromal Tumor Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Gastrointestinal Stromal Tumor Drug Market by Company

China Biopharmaceuticals

Zai Lab

CSPC Pharmaceuticals

Novartis

Mylan Pharms Inc.

Kelun Pharmaceuticals

CStone Pharmaceuticals

Hansoh Pharmaceuticals

Vannsh Life Sciences

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceuticals

MSN Laboratories

Glenmark Pharmaceuticals Ltd.

Drug International

Dr. Reddy's Laboratories

Deciphera Pharmaceuticals

Bulat Pharmaceutical

Beacon Pharmaceuticals

Bayer Pharmaceuticals

Apotex Inc.

Actavis Generics

Gastrointestinal Stromal Tumor Drug Segment by Type

Ripretinib

Regorafenib

Sunitinib

Imatinib

Others

Gastrointestinal Stromal Tumor Drug Segment by Application

Hospital

Clinic

Others

Gastrointestinal Stromal Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Stromal Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Stromal Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Stromal Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Gastrointestinal Stromal Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ripretinib Table 2. Major Company of Regorafenib Table 3. Major Company of Sunitinib Table 4. Major Company of Imatinib Table 5. Major Company of Others Table 6. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (K Units) Table 8. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Gastrointestinal Stromal Tumor Drug Price by Type (2021-2026) & (US$/Unit) Table 12. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2027-2032) & (K Units) Table 13. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Gastrointestinal Stromal Tumor Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Gastrointestinal Stromal Tumor Drug Price by Type (2027-2032) & (US$/Unit) Table 17. North America Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (K Units) Table 18. North America Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (K Units) Table 20. Europe Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (K Units) Table 24. Latin America Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Gastrointestinal Stromal Tumor Drug Industry Trends Table 28. Gastrointestinal Stromal Tumor Drug Industry Drivers Table 29. Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges Table 30. Gastrointestinal Stromal Tumor Drug Industry Restraints Table 31. Global Gastrointestinal Stromal Tumor Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Company (2021-2026) Table 33. Global Gastrointestinal Stromal Tumor Drug Sales by Company (2021-2026) & (K Units) Table 34. Global Gastrointestinal Stromal Tumor Drug Sales Share by Company (2021-2026) Table 35. Global Gastrointestinal Stromal Tumor Drug Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Gastrointestinal Stromal Tumor Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Gastrointestinal Stromal Tumor Drug Major Company Production Sites and Headquarters Table 38. Global Gastrointestinal Stromal Tumor Drug Company, Product Type & Application Table 39. Global Gastrointestinal Stromal Tumor Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Gastrointestinal Stromal Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Gastrointestinal Stromal Tumor Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Gastrointestinal Stromal Tumor Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2027-2032) & (K Units) Table 60. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Gastrointestinal Stromal Tumor Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Gastrointestinal Stromal Tumor Drug Price by Application (2027-2032) & (US$/Unit) Table 64. North America Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (K Units) Table 65. North America Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (K Units) Table 67. Europe Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (K Units) Table 71. Latin America Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Application (2021-2026) & (US$ Million) Table 74. China Biopharmaceuticals Company Information Table 75. China Biopharmaceuticals Business Overview Table 76. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 78. China Biopharmaceuticals Recent Development Table 79. Zai Lab Company Information Table 80. Zai Lab Business Overview Table 81. Zai Lab Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio Table 83. Zai Lab Recent Development Table 84. CSPC Pharmaceuticals Company Information Table 85. CSPC Pharmaceuticals Business Overview Table 86. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 88. CSPC Pharmaceuticals Recent Development Table 89. Novartis Company Information Table 90. Novartis Business Overview Table 91. Novartis Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio Table 93. Novartis Recent Development Table 94. Mylan Pharms Inc. Company Information Table 95. Mylan Pharms Inc. Business Overview Table 96. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 98. Mylan Pharms Inc. Recent Development Table 99. Kelun Pharmaceuticals Company Information Table 100. Kelun Pharmaceuticals Business Overview Table 101. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 103. Kelun Pharmaceuticals Recent Development Table 104. CStone Pharmaceuticals Company Information Table 105. CStone Pharmaceuticals Business Overview Table 106. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 108. CStone Pharmaceuticals Recent Development Table 109. Hansoh Pharmaceuticals Company Information Table 110. Hansoh Pharmaceuticals Business Overview Table 111. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 113. Hansoh Pharmaceuticals Recent Development Table 114. Vannsh Life Sciences Company Information Table 115. Vannsh Life Sciences Business Overview Table 116. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio Table 118. Vannsh Life Sciences Recent Development Table 119. Teva Pharmaceutical Industries Ltd. Company Information Table 120. Teva Pharmaceutical Industries Ltd. Business Overview Table 121. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 123. Teva Pharmaceutical Industries Ltd. Recent Development Table 124. Sun Pharmaceuticals Company Information Table 125. Sun Pharmaceuticals Business Overview Table 126. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 128. Sun Pharmaceuticals Recent Development Table 129. MSN Laboratories Company Information Table 130. MSN Laboratories Business Overview Table 131. MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio Table 133. MSN Laboratories Recent Development Table 134. Glenmark Pharmaceuticals Ltd. Company Information Table 135. Glenmark Pharmaceuticals Ltd. Business Overview Table 136. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 138. Glenmark Pharmaceuticals Ltd. Recent Development Table 139. Drug International Company Information Table 140. Drug International Business Overview Table 141. Drug International Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio Table 143. Drug International Recent Development Table 144. Dr. Reddy's Laboratories Company Information Table 145. Dr. Reddy's Laboratories Business Overview Table 146. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio Table 148. Dr. Reddy's Laboratories Recent Development Table 149. Deciphera Pharmaceuticals Company Information Table 150. Deciphera Pharmaceuticals Business Overview Table 151. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 153. Deciphera Pharmaceuticals Recent Development Table 154. Bulat Pharmaceutical Company Information Table 155. Bulat Pharmaceutical Business Overview Table 156. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio Table 158. Bulat Pharmaceutical Recent Development Table 159. Beacon Pharmaceuticals Company Information Table 160. Beacon Pharmaceuticals Business Overview Table 161. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 163. Beacon Pharmaceuticals Recent Development Table 164. Bayer Pharmaceuticals Company Information Table 165. Bayer Pharmaceuticals Business Overview Table 166. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 168. Bayer Pharmaceuticals Recent Development Table 169. Apotex Inc. Company Information Table 170. Apotex Inc. Business Overview Table 171. Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 173. Apotex Inc. Recent Development Table 174. Actavis Generics Company Information Table 175. Actavis Generics Business Overview Table 176. Actavis Generics Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio Table 178. Actavis Generics Recent Development Table 179. North America Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 180. North America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 181. North America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2026) Table 182. North America Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032) & (K Units) Table 183. North America Gastrointestinal Stromal Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 184. North America Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 185. North America Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 186. North America Gastrointestinal Stromal Tumor Drug Market Share by Country (2021-2026) Table 187. North America Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 188. North America Gastrointestinal Stromal Tumor Drug Market Share Forecast by Country (2027-2032) Table 189. Europe Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 190. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 191. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2026) Table 192. Europe Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032) & (K Units) Table 193. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 194. Europe Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 195. Europe Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 196. Europe Gastrointestinal Stromal Tumor Drug Market Share by Country (2021-2026) Table 197. Europe Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 198. Europe Gastrointestinal Stromal Tumor Drug Market Share Forecast by Country (2027-2032) Table 199. Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 200. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 201. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2026) Table 202. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032) & (K Units) Table 203. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 204. Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 205. Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 206. Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Share by Country (2021-2026) Table 207. Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 208. Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Share Forecast by Country (2027-2032) Table 209. Latin America Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 210. Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 211. Latin America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2026) Table 212. Latin America Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032) & (K Units) Table 213. Latin America Gastrointestinal Stromal Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 214. Latin America Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 215. Latin America Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 216. Latin America Gastrointestinal Stromal Tumor Drug Market Share by Country (2021-2026) Table 217. Latin America Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 218. Latin America Gastrointestinal Stromal Tumor Drug Market Share Forecast by Country (2027-2032) Table 219. Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 220. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 221. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2026) Table 222. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032) & (K Units) Table 223. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share Forecast by Country (2027-2032) Table 224. Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 225. Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 226. Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Share by Country (2021-2026) Table 227. Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 228. Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Share Forecast by Country (2027-2032) Table 229. Key Raw Materials Table 230. Raw Materials Key Suppliers Table 231. Gastrointestinal Stromal Tumor Drug Distributors List Table 232. Gastrointestinal Stromal Tumor Drug Customers List Table 233. Research Programs/Design for This Report Table 234. Authors List of This Report Table 235. Secondary Sources Table 236. Primary Sources List of Figures Figure 1. Gastrointestinal Stromal Tumor Drug Image Figure 2. Global Gastrointestinal Stromal Tumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastrointestinal Stromal Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Gastrointestinal Stromal Tumor Drug Sales (2021-2032) & (K Units) Figure 5. Ripretinib Image Figure 6. Global Ripretinib Sales YoY Growth (2021-2032) & (K Units) Figure 7. Regorafenib Image Figure 8. Global Regorafenib Sales YoY Growth (2021-2032) & (K Units) Figure 9. Sunitinib Image Figure 10. Global Sunitinib Sales YoY Growth (2021-2032) & (K Units) Figure 11. Imatinib Image Figure 12. Global Imatinib Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Gastrointestinal Stromal Tumor Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Gastrointestinal Stromal Tumor Drug Market Share by Type 2025 VS 2032 Figure 17. North America Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Gastrointestinal Stromal Tumor Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Gastrointestinal Stromal Tumor Drug Market Share by Application 2025 VS 2032 Figure 37. North America Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Gastrointestinal Stromal Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Gastrointestinal Stromal Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Gastrointestinal Stromal Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Gastrointestinal Stromal Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Gastrointestinal Stromal Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Gastrointestinal Stromal Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Gastrointestinal Stromal Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Gastrointestinal Stromal Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Gastrointestinal Stromal Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Gastrointestinal Stromal Tumor Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Gastrointestinal Stromal Tumor Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Ripretinib
  • Regorafenib
  • Sunitinib
  • Imatinib
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • China Biopharmaceuticals
  • Zai Lab
  • CSPC Pharmaceuticals
  • Novartis
  • Mylan Pharms Inc.
  • Kelun Pharmaceuticals
  • CStone Pharmaceuticals
  • Hansoh Pharmaceuticals
  • Vannsh Life Sciences
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceuticals
  • MSN Laboratories
  • Glenmark Pharmaceuticals Ltd.
  • Drug International
  • Dr. Reddy's Laboratories
  • Deciphera Pharmaceuticals
  • Bulat Pharmaceutical
  • Beacon Pharmaceuticals
  • Bayer Pharmaceuticals
  • Apotex Inc.
  • Actavis Generics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gastrointestinal Stromal Tumor Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Gastrointestinal Stromal Tumor Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Gastrointestinal Stromal Tumor Drug Market by Type
  6. 1.3.1 Ripretinib
  7. 1.3.2 Regorafenib
  8. 1.3.3 Sunitinib
  9. 1.3.4 Imatinib
  10. 1.3.5 Others
  11. 1.4 Global Gastrointestinal Stromal Tumor Drug Market Size by Type
  12. 1.4.1 Global Gastrointestinal Stromal Tumor Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Gastrointestinal Stromal Tumor Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Gastrointestinal Stromal Tumor Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Gastrointestinal Stromal Tumor Drug Industry Trends
  2. 2.2 Gastrointestinal Stromal Tumor Drug Industry Drivers
  3. 2.3 Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Gastrointestinal Stromal Tumor Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Gastrointestinal Stromal Tumor Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Gastrointestinal Stromal Tumor Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Gastrointestinal Stromal Tumor Drug Price (2021-2026)
  4. 3.4 Global Gastrointestinal Stromal Tumor Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Gastrointestinal Stromal Tumor Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Gastrointestinal Stromal Tumor Drug Company, Product Type & Application
  7. 3.7 Global Gastrointestinal Stromal Tumor Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Gastrointestinal Stromal Tumor Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Gastrointestinal Stromal Tumor Drug Tier 1, Tier 2, and Tier 3
4 Gastrointestinal Stromal Tumor Drug Regional Status and Outlook
  1. 4.1 Global Gastrointestinal Stromal Tumor Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Gastrointestinal Stromal Tumor Drug Historic Market Size by Region
  3. 4.2.1 Global Gastrointestinal Stromal Tumor Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Gastrointestinal Stromal Tumor Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Gastrointestinal Stromal Tumor Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Gastrointestinal Stromal Tumor Drug Forecasted Market Size by Region
  7. 4.3.1 Global Gastrointestinal Stromal Tumor Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Gastrointestinal Stromal Tumor Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Gastrointestinal Stromal Tumor Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Gastrointestinal Stromal Tumor Drug by Application
  1. 5.1 Gastrointestinal Stromal Tumor Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Gastrointestinal Stromal Tumor Drug Market Size by Application
  6. 5.2.1 Global Gastrointestinal Stromal Tumor Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Gastrointestinal Stromal Tumor Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Gastrointestinal Stromal Tumor Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 China Biopharmaceuticals
  2. 6.1.1 China Biopharmaceuticals Company Information
  3. 6.1.2 China Biopharmaceuticals Business Overview
  4. 6.1.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  6. 6.1.5 China Biopharmaceuticals Recent Developments
  7. 6.2 Zai Lab
  8. 6.2.1 Zai Lab Company Information
  9. 6.2.2 Zai Lab Business Overview
  10. 6.2.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
  12. 6.2.5 Zai Lab Recent Developments
  13. 6.3 CSPC Pharmaceuticals
  14. 6.3.1 CSPC Pharmaceuticals Company Information
  15. 6.3.2 CSPC Pharmaceuticals Business Overview
  16. 6.3.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  18. 6.3.5 CSPC Pharmaceuticals Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Mylan Pharms Inc.
  26. 6.5.1 Mylan Pharms Inc. Company Information
  27. 6.5.2 Mylan Pharms Inc. Business Overview
  28. 6.5.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
  30. 6.5.5 Mylan Pharms Inc. Recent Developments
  31. 6.6 Kelun Pharmaceuticals
  32. 6.6.1 Kelun Pharmaceuticals Company Information
  33. 6.6.2 Kelun Pharmaceuticals Business Overview
  34. 6.6.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  36. 6.6.5 Kelun Pharmaceuticals Recent Developments
  37. 6.7 CStone Pharmaceuticals
  38. 6.7.1 CStone Pharmaceuticals Company Information
  39. 6.7.2 CStone Pharmaceuticals Business Overview
  40. 6.7.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  42. 6.7.5 CStone Pharmaceuticals Recent Developments
  43. 6.8 Hansoh Pharmaceuticals
  44. 6.8.1 Hansoh Pharmaceuticals Company Information
  45. 6.8.2 Hansoh Pharmaceuticals Business Overview
  46. 6.8.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  48. 6.8.5 Hansoh Pharmaceuticals Recent Developments
  49. 6.9 Vannsh Life Sciences
  50. 6.9.1 Vannsh Life Sciences Company Information
  51. 6.9.2 Vannsh Life Sciences Business Overview
  52. 6.9.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
  54. 6.9.5 Vannsh Life Sciences Recent Developments
  55. 6.10 Teva Pharmaceutical Industries Ltd.
  56. 6.10.1 Teva Pharmaceutical Industries Ltd. Company Information
  57. 6.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
  58. 6.10.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
  60. 6.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  61. 6.11 Sun Pharmaceuticals
  62. 6.11.1 Sun Pharmaceuticals Company Information
  63. 6.11.2 Sun Pharmaceuticals Business Overview
  64. 6.11.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  66. 6.11.5 Sun Pharmaceuticals Recent Developments
  67. 6.12 MSN Laboratories
  68. 6.12.1 MSN Laboratories Company Information
  69. 6.12.2 MSN Laboratories Business Overview
  70. 6.12.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
  72. 6.12.5 MSN Laboratories Recent Developments
  73. 6.13 Glenmark Pharmaceuticals Ltd.
  74. 6.13.1 Glenmark Pharmaceuticals Ltd. Company Information
  75. 6.13.2 Glenmark Pharmaceuticals Ltd. Business Overview
  76. 6.13.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
  78. 6.13.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  79. 6.14 Drug International
  80. 6.14.1 Drug International Company Information
  81. 6.14.2 Drug International Business Overview
  82. 6.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
  84. 6.14.5 Drug International Recent Developments
  85. 6.15 Dr. Reddy's Laboratories
  86. 6.15.1 Dr. Reddy's Laboratories Company Information
  87. 6.15.2 Dr. Reddy's Laboratories Business Overview
  88. 6.15.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
  90. 6.15.5 Dr. Reddy's Laboratories Recent Developments
  91. 6.16 Deciphera Pharmaceuticals
  92. 6.16.1 Deciphera Pharmaceuticals Company Information
  93. 6.16.2 Deciphera Pharmaceuticals Business Overview
  94. 6.16.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  96. 6.16.5 Deciphera Pharmaceuticals Recent Developments
  97. 6.17 Bulat Pharmaceutical
  98. 6.17.1 Bulat Pharmaceutical Company Information
  99. 6.17.2 Bulat Pharmaceutical Business Overview
  100. 6.17.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
  102. 6.17.5 Bulat Pharmaceutical Recent Developments
  103. 6.18 Beacon Pharmaceuticals
  104. 6.18.1 Beacon Pharmaceuticals Company Information
  105. 6.18.2 Beacon Pharmaceuticals Business Overview
  106. 6.18.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  108. 6.18.5 Beacon Pharmaceuticals Recent Developments
  109. 6.19 Bayer Pharmaceuticals
  110. 6.19.1 Bayer Pharmaceuticals Company Information
  111. 6.19.2 Bayer Pharmaceuticals Business Overview
  112. 6.19.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  114. 6.19.5 Bayer Pharmaceuticals Recent Developments
  115. 6.20 Apotex Inc.
  116. 6.20.1 Apotex Inc. Company Information
  117. 6.20.2 Apotex Inc. Business Overview
  118. 6.20.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
  120. 6.20.5 Apotex Inc. Recent Developments
  121. 6.21 Actavis Generics
  122. 6.21.1 Actavis Generics Company Information
  123. 6.21.2 Actavis Generics Business Overview
  124. 6.21.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
  126. 6.21.5 Actavis Generics Recent Developments
7 North America by Country
  1. 7.1 North America Gastrointestinal Stromal Tumor Drug Sales by Country
  2. 7.1.1 North America Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Gastrointestinal Stromal Tumor Drug Market Size by Country
  6. 7.2.1 North America Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Gastrointestinal Stromal Tumor Drug Sales by Country
  2. 8.1.1 Europe Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Gastrointestinal Stromal Tumor Drug Market Size by Country
  6. 8.2.1 Europe Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Country
  2. 9.1.1 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Gastrointestinal Stromal Tumor Drug Sales by Country
  2. 10.1.1 South America Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Gastrointestinal Stromal Tumor Drug Market Size by Country
  6. 10.2.1 South America Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country
  2. 11.1.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Gastrointestinal Stromal Tumor Drug Value Chain Analysis
  2. 12.1.1 Gastrointestinal Stromal Tumor Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Gastrointestinal Stromal Tumor Drug Production Mode & Process
  7. 12.2 Gastrointestinal Stromal Tumor Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Gastrointestinal Stromal Tumor Drug Distributors
  10. 12.2.3 Gastrointestinal Stromal Tumor Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst